Heparin-induced thrombocytopenia, part 2: Clinical course and treatment. How can drug selection help spare life and limb?

Journal of Critical Illness

Volumn 17, Issue 6, 2002, Pages 215-221

  Warkentin, Theodore E ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; DANAPAROID; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; WARFARIN;

ALGORITHM; ARTICLE; AUTOPSY; DISEASE COURSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG WITHDRAWAL; GANGRENE; HUMAN; IMMUNOASSAY; INTERNATIONAL STANDARD UNIT; LUNG EMBOLISM; MEDICAL DECISION MAKING; MEDICOLEGAL ASPECT; PROTEIN DEPLETION; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036089552     PISSN: 10400257     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Treatment of heparin-induced thrombocytopenia: An overview
2. Heparin-induced thrombocytopenia: Yet another treatment paradox?
3. Medicolegal aspects of heparin-induced thrombocytopenia: US perspective
4. A 14-year study of heparin-induced thrombocytopenia
5. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
6. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
7. A comparison of lepirudin and danaparoid in heparin-induced thrombocytopenia
8. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia
9. Heparin-induced thrombocytopenia complicated by bilateral adrenal haemorrhage
10. Transient global amnesia associated with acute heparin-induced thrombocytopenia
11. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
12. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia
13. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis
14. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
15. Impact of the patient population on the risk for heparin-induced thrombocytopenia
16. Frequency of heparin-induced thrombocytopenia
17. The use of low-molecular-weight heparins in heparin-induced thrombocytopenia (HIT): A cohort study
18. Clinical picture of heparin-induced thrombocytopenia
19. The appropriate use of platelets: An update from the Edinburgh Consensus Conference
20. Limitations of conventional treatment options for heparin-induced thrombocytopenia
21. Danaparoid for the treatment of heparin-induced thrombocytopenia
22. Danaparoid (Orgaran®) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: Effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG
23. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia
24. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia
25. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
26. Argatroban therapy in heparin-induced thrombocytopenia
27. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
28. Warfarin-induced skin necrosis and venous limb gangrene with heparin induced thrombocytopenia
29. Bivalirudin (Angiomax) for angioplasty
30. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog
31. Temporal aspects of heparin-induced thrombocytopenia
32. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia
33. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia
34. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia